• LAST PRICE
    235.2300
  • TODAY'S CHANGE (%)
    Trending Up2.1600 (0.9268%)
  • Bid / Lots
    234.5500/ 2
  • Ask / Lots
    235.9100/ 7
  • Open / Previous Close
    232.3600 / 233.0700
  • Day Range
    Low 231.9300
    High 236.3700
  • 52 Week Range
    Low 148.0000
    High 277.3400
  • Volume
    18,718
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 233.07
TimeVolumePEN
09:32 ET2152232.265
09:35 ET116233.79
09:39 ET200232.165
09:46 ET100231.93
09:53 ET1070232.515
09:55 ET1321233.4927
09:57 ET5326235.07
10:02 ET200235.45
10:04 ET429235.905
10:06 ET2063235.0213
10:08 ET105235.125
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPEN
Penumbra Inc
8.9B
273.5x
+65.82%
United StatesMASI
Masimo Corp
8.6B
111.6x
-15.37%
United StatesRGEN
Repligen Corp
8.1B
-3,372.7x
+15.08%
United StatesSTVN
Stevanato Group SpA
6.9B
49.1x
---
United StatesGKOS
Glaukos Corp
7.7B
-46.7x
---
United StatesTFX
Teleflex Inc
9.3B
39.4x
+12.49%
As of 2024-11-08

Company Information

Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.

Contact Information

Headquarters
One Penumbra PlaceALAMEDA, CA, United States 94502
Phone
510-748-3200
Fax
302-531-3150

Executives

Chairman of the Board, President, Chief Executive Officer
Adam Elsesser
Chief Financial Officer
Maggie Yuen
Executive Vice President, General Counsel, Secretary
Johanna Roberts
Chief Accounting Officer
Lambert Shiu
Director
Arani Bose

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$8.9B
Revenue (TTM)
$1.2B
Shares Outstanding
38.4M
Penumbra Inc does not pay a dividend.
Beta
0.50
EPS
$0.86
Book Value
$30.48
P/E Ratio
273.5x
Price/Sales (TTM)
7.7
Price/Cash Flow (TTM)
146.9x
Operating Margin
0.13%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.